SHP.L : Summary for SHIRE PLC ORD 5P - Yahoo Finance

U.S. Markets closed

Shire plc (SHP.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
4,589.50+35.00 (+0.77%)
At close: 12:11 PM EST
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close4,554.50
Bid4,500.00 x 51000
Ask4,630.00 x 53800
Day's Range4,510.00 - 4,625.50
52 Week Range2,707.19 - 5,562.83
Avg. Volume2,462,585
Market Cap41.16B
PE Ratio (TTM)210.53
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • InPlay from
    Briefing.com17 hours ago

    InPlay from

    InPlay from

  • PR Newswire17 hours ago

    Shire Reports on Four Decades of Real-World Safety Experience With FEIBA®

    Shire plc (LSE: SHP; NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare diseases, is presenting an update on its safety database describing 40 years of real-world experience with the bypassing agent FEIBA [Anti-Inhibitor Coagulant Complex]. Shire also revealed new in vitro data showing the potential for excessive thrombin generation when combining an investigational procoagulant bispecific antibody and bypass therapy for breakthrough bleeds. Recently, concerns have emerged related to the use of an investigational non-factor product when combined with marketed bypassing agents for hemophilia patients with inhibitors.

  • PR Newswireyesterday

    Topline Results of Phase 3 Investigational Study of VONVENDI™ Meets Primary Endpoint Effectively Controlling Bleeding and Blood Loss During Surgical Procedures

    Shire plc (LSE: SHP, NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare diseases and other highly specialized conditions, today announced topline results from a Phase 3 clinical trial of VONVEND™I [von Willebrand factor (Recombinant)] to treat bleeds in elective surgical settings for adults with severe von Willebrand disease (VWD), the most common inherited bleeding disorder. VONVENDI is an on-demand recombinant treatment for adults living with VWD and replaces von Willebrand factor (VWF), one of several types of proteins in the blood that are needed to facilitate proper blood clotting missing in patients with VWD.[1] The study met its primary endpoint and indicates that VONVENDI effectively controlled bleeding and blood loss during an operation in adults undergoing major, minor and oral elective surgical procedures.